Since its establishment in 1999, Sejong Medix has led pharmaceutical distribution with accumulated expertise and technical capability. The company was the first in Korea to supply calcium citrate, opened the scar-therapy market when it was still undeveloped, and now exclusively supplies Kelo-Cote, an FDA-cleared device protected by a U.S. patent, earning the confidence of the medical community.
We also contribute to public health by advancing the development of anti-aging injectables.
To provide the optimal therapeutic solutions required in clinical practice, Sejong Medix is fully committed to leading technology development, research, and rigorous quality control. We regard this as our corporate social responsibility and pursue it with unwavering dedication.
Sejong Medix will stand behind compassionate medicine. We will walk with you on the path that protects people from disease and makes life more fulfilling.
Thank you.
Cheol-ryeon Kim, Chief Executive Officer, Sejong Medix Co., Ltd.
